J. Paul Scott, MD        

Titles
Pediatric hematologist, Children's Hospital of Wisconsin; professor, Pediatrics, Medical College of Wisconsin.

Division
Hematology, Oncology and Transplant

Research center/program
Bleeding disorders research

Research interests
Bleeding and blood disorders

Study interests
Hemostasis, neurocognitive impact, novel therapeutics, sickle cell anemia, stroke, vascular biology.

Education
Medical degree, Loyola University Stritch School of Medicine, Maywood, Ill., 1974; residency, Pediatrics, University of Colorado Health Sciences Center, Denver, 1974-1977; fellowship, Pediatric Hematology-Oncology, University of Colorado Medical Center, Denver, 1977-1979.

Certifications
Pediatrics, 1980; Pediatric Hematology-Oncology, 1982.              

Honors
Teacher of the Year, Children's Memorial Hospital; Northwestern Medical School, Department of Pediatrics, 1983; Outstanding Teacher of the Year, Children's Hospital of Wisconsin, 1998; Outstanding Teacher of the Year, Children's Hospital of Wisconsin, Medical College of Wisconsin, Department of Pediatrics, 2002.              

Representative publications

• Talano JA, Hillery CA,Gottschall JL, Baylerian DM, Scott JP. Delayed Hemolytic Transfusion Reaction/hyperhemolysis Syndrome in Children with Sickle Cell Disease. Pediatrics. 111(6 Pt 1):e661-5, 2003.
• Melzer-Lange MD, Walsh-Kelly CM, Lea G, Hillery CA, Scott JP. Patient-controlled Analgesia for Sickle Cell Pain Crisis in a Pediatric Emergency Department. Pediatric Emergency Care. 2004 Jan.; 20(1):2-4.
• Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea Therapy Decreases Red Blood Cell Adhesion to Thrombospondin and Laminin in Sickle Cell Disease. British Journal of Haematology. 2000; 109:322-327.
• Bevan JA, Maloney KW, Hillery CA, Gill JC, Montgomery RR, Scott JP. Bleeding Disorders: A Common Cause of Menorrhagia in Adolescents. Journal of Pediatrics. 2001 Jun.; 138(6):856-861.
• Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A Two-year Pilot Trial of Hydroxyurea in very Young Children with Sickle Cell Anemia. Journal of Pediatrics. 2001 Dec.; 139(6):790-796.
• Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Hydroxyurea Therapy in Children Severely Affected with Sickle Cell Disease. Journal of Pediatrics. 1996; 128:820-828.

Grants

• Wisconsin Sickle Cell Disease Comprehensive Center; current year $271,736, State of Wisconsin, Newborn Screening Program, principal investigator (25 percent effort).
• An Intervention Program for Children with Sickle Cell Disease: An Opportunity to Improve School Performance and Psychosocial Adjustment, Children's Hospital and Health System Foundation, $200,000, principal investigator.
• Mechanisms of Vaso-occlusion in Sickle Cell Disease: Role of Coagulation Pathways, NIH P01-HL44612 (PI of PPG: Peter Newman), 5/1/00 to 6/30/05; Project 4 PI: Cheryl Hillery; Co-I: JP Scott, Amount (Project 4): Direct $828,492 plus Core support, 5/1/00 to 4/30/05.
• Red Blood Cell Adhesion in Sickle Cell Disease, NIH R01-HL70981, PI: Cheryl Hillery; Co-I: J.P. Scott; 7/1/02 to 6/30/06, $900,000.

Contact
Children's Hospital of Wisconsin
PO Box 1997
Milwaukee, WI 53201-1997
Phone: (414) 937-3896
Fax: (414) 937-3804
E-mail: jpscott@bcw.edu